Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C61H88N18O21S2 |
Molecular Weight | 1473.589 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]7(O[C@@H]1[C@H](O[C@H]([C@H](NC(=O)C2=NC(=NC(N)=C2C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC3=NC(=CS3)C4=NC(=CS4)C(=O)NCCCN[C@@H](C)C5=CC=CC=C5)C6=CN=CN6)O[C@@H](CO)[C@@H](O)[C@@H]1O)O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]7O
InChI
InChIKey=QIMGFXOHTOXMQP-GFAGFCTOSA-N
InChI=1S/C61H88N18O21S2/c1-24-39(76-52(79-50(24)64)31(16-37(63)83)71-17-30(62)51(65)89)56(93)78-41(47(32-18-67-23-72-32)98-60-49(45(87)43(85)35(19-80)97-60)99-59-46(88)48(100-61(66)95)44(86)36(20-81)96-59)57(94)73-27(4)42(84)25(2)53(90)77-40(28(5)82)55(92)70-15-12-38-74-34(22-101-38)58-75-33(21-102-58)54(91)69-14-9-13-68-26(3)29-10-7-6-8-11-29/h6-8,10-11,18,21-23,25-28,30-31,35-36,40-49,59-60,68,71,80-82,84-88H,9,12-17,19-20,62H2,1-5H3,(H2,63,83)(H2,65,89)(H2,66,95)(H,67,72)(H,69,91)(H,70,92)(H,73,94)(H,77,90)(H,78,93)(H2,64,76,79)/t25-,26-,27+,28+,30-,31-,35-,36+,40-,41-,42-,43+,44+,45-,46-,47-,48-,49-,59+,60-/m0/s1
Molecular Formula | C61H88N18O21S2 |
Molecular Weight | 1473.589 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/83987 | http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/83987 | http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236
Peplomycin has been developed as novel analog of bleomycin, which has less pulmonary toxicity than bleomycin. Peplomycin has been the subject of extensive studies in Japan and Europe. It is indicated for the treatment of malignant lymphoma, head and neck cancer, lung cancer, prostate cancer and skin cancer. General side effects are: digestive symptoms such as stomatitis, anorexia, nausea/vomiting, general malaise, depilation, fever, chills etc.
Originator
Sources: http://iss.ndl.go.jp/books/R000000004-I1917102-00
Curator's Comment: https://www.google.ch/patents/US4238391
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP1925 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Pepleo Approved UseIt is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma |
|||
Primary | Pepleo Approved UseIt is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma |
|||
Primary | Pepleo Approved UseIt is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma |
|||
Primary | Pepleo Approved UseIt is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma |
|||
Primary | Pepleo Approved UseIt is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma |
Sample Use Guides
3.2 mg/m2 once a day, 2-3 times per week (22.4 mg/m2 per week)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/83987
Peplomycin showed the following antimicrobial potency against Mycobacterium smegmatis ATCC 607 – 873 ug potency/mg and gave the following very correlative result on the growth inhibition of cultured HeLa S3 cells – ID50 = 0.84 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:38:51 GMT 2023
by
admin
on
Fri Dec 15 18:38:51 GMT 2023
|
Record UNII |
56H9L80NIZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2311
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2111003
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
6852373
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
2965
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
68247-85-8
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
D017663
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
SUB09708MIG
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
56H9L80NIZ
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
C1399
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
269-484-0
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
4833
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
DTXSID701024414
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | |||
|
m8527
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000082539
Created by
admin on Fri Dec 15 18:38:51 GMT 2023 , Edited by admin on Fri Dec 15 18:38:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |